earnings grew by at X%, call combined company. results quarter, the taking thank X% afternoon, adjusted was The the Beckman financial a join driven and of quarter. EPS revenue I a a as quarter transfusion we margin time Adjusted grew call solid BNP assay for point care and of base achieved which the percentage and Thanks, in in results headwind minutes. detail and EBITDA raise the in the the good point in today, three results Bryan. COVID-related constant revenue for businesses. transition will further full reporting our of Joe everybody, the growth, Good XX% currency our year, These to business headwinds our very year, in despite us are first operating When you better-than-expected few look industry-wide guidance of share third this strength $X.XX revenue excluding medicine quarter. the underlying leverage to our to for for year-over-year and position which reflect
four, remainder two, the are: the our integration corporate that capital strategic will and and three, deployment. product of For call, outlined Beginning operational corporate and innovation; comments, I which the my focus five, commercial culture; integration on earnings global I one, priorities on excellence; our culture. with excellence; last
of especially the for executive attributes both I've the and me. cultures organizations of top preserving previously, As for the the is best priority the mentioned integration and team
across last integration. integrated, a While operations team's organization as days even to the initially the our The IT, customer transaction, legal, the the strong four HR, its that agility And R&D, levels among business the start. joining implemented demonstrated of we've achieving across new and fully we're purpose executive finance, two office over structure, the exceeded early weren't in optimize team it's our to off established. our teams Many the have are the quarter, company, have below and expectations. teams leadership my units full service of chief structures, shared communication team and exceptional collaboration since still processes say I entire focus, systems that close must and introduced operations. new
in identified Our to integrated. integrate are and by of commercial quarter. be U.S. last end U.S. are communicated. year, this We've the also Product the team. to the the structure fully and is first The remaining team every organizational outside will training the role, commercial expected new begin fully teams cross-selling
With our and leadership entire levels, identified milestone real down through executive completed, a operating and team now strengthens that the all the substantially announced of impact aligns from supporting our we've structure the organizational work organization.
integration, strides significant made work we've Although continues. in our
have combination group to integrations is that results our a process integrations with are excellent Teams to deliver we employee responses. been that management accomplished don't and favor favorable combined always significant prouder demonstrated less complete survey and integration, our don't turnover be preliminary more our and than manufacturing couldn't very on part and we efficiencies. with integration planning the progress. our and we is the commercial integration bigger, To assets, confidence that the with engaged, services of to need engagement XXXX challenging, consolidating the the involvement are for of quarter operational talent streams and strategic facilities, teamwork and of overlap while to teams simpler of levels, team end, cooperative rate we processes employee start recent continues dependence we what fully This securing our have certainly through collaborative execute the in transition show needed low commitments active employee is other the Ortho the growth. to largely aren't happy I very business. the believe Our the of are happiness highlights what another. on strong, milestones required we've when product well drive one at and sustainable identified attract state although any culture in because and the high creating. than expected Moreover, announced company complex merger, the on that response XX successfully have us very operate professional, Alere of and work third-party first companies. integration we combination a straightforward The two-year our giving program priorities, our the opportunities employees on and continued and This future been process product Quidel selling saying, embracing is
cost turning Now to synergies.
target. We have now million well identified million at in XXXX $XX cost synergies least $XX our above
our further process We are upside. annual and believe amid there could that operating plan be
Moving on innovation. to product
and projects, are approximately opportunity there's to our We spend. managing XXX and our optimize R&D focus
resources initiated is rank based our review that NPVs been regulatory to the portfolio risks. During and projects. an us projects for largely helping adjusted for the This we important R&D on most technical, market have prioritize quarter,
can As and Dry of screening our most Leapfrog, Q next-generation the long-term important projects imagine, R&D to Savanna, many Ortho include vitro [ph]. Other Sofia advance which used our projects in Dry to platform, call are exciting portfolios. Sofia donor you
expand further of We my Today, focus Labs, Sofia. all Savanna at and Day. these Investor our comments on will on December I'll
business. First, our Labs
refreshed business enables our the China and chemistry importantly, For approval reliability. improved next-generation regulatory for vitros-XTXXXX and the seven will by China's launched the And clearance throughput, second we accelerate planned Labs growth this received quarter With in introducing system new a system. unit that best-in-class testing globally. assays and this technology commercialization row, strategy imaging accuracy higher QX, in digital testing
of vitro's impact China, manufacturing in requirements of and the line XXXX. planning have are an efforts these analyzers to for expect given in We localization
Secondly, Savanna.
demand confident placements XXXX. are and throughout and We will accelerate revenue in Savanna seeing increasingly are that Europe
and we cartridges. and manufacturing supply We production to continue on of instruments chain ramp as up focus both challenges overcoming
in Additionally, XXX(k) for clearance are authorization Savanna launch now XXXX. full the And we Savanna in surest the is completed there believe use path we development planned emergency regulatory signs to CLIA include the activities to panels expedited immediately of instruments and that that panels U.S., and changing. for is all availability waivers. pathway for FDA Yet
in both possible. We and regulatory quickly the commercial making can so we that as our as bring to are that shift market U.S. strategy Savanna
and U.S. and U.S. Given government select firmly of near-term Middle revenue believe Savanna and warranted in the valuable are for CE other XXX in push in both have support And gather could the said, output all full concerted commercial our we planned Mark Europe, respiratory year. companies our the That clearances XXXX. in the other launch place, opportunity in stages we placement and panels and global already in East of on QX for Middle our Europe, by data East activities With season, is including instruments can demand we U.S. we Sofia. moving the achieve our on we finally, the and Africa team targets where Africa to about plan, limited support a the later forward to molecular launching launch Europe commercial strong countries. concentrating versus are product
While anticipated rates is revenue or and the months peak instrument basis, of sooner reached third respiratory typical in diseases, than in influenza Overall, has the respiratory Mid-Atlantic, began our positivity XX Southeast since virus Midwest. now in quarter non-COVID had RSV. months rates menu. the XX revenue activity with strengthen, have high just ILI a COVID-XX, XX.X%, the increasing season seen therefore driven positivity of On rates CDC QuidelOrtho's increasing beginning, continues full U.S. data highest non-flu the indicate cases highest climb. have and season and by The Virena was reported test higher influenza respiratory positivity than the per including the and we is for was a in XXXX in Sofia Influenza quarter. trailing to continue the and to
build healthy them last we higher significantly in much significantly which several see didn't which As quarter, anticipated, up placements influenza from strep, our see RSV we tests influenza than but are quarter, new instruments, up Sofia may over total stock smaller suggest the demand volumes. distributors now next inventories placement for XX,XXX quarters. instrument Moreover, the cumulative did XX,XXX and
distribution U.S. The Quidel the global in multiplier maintained success offices, banks, developed third To with Next, of that a and representatives excellence, are representatives team force retailers commercial clinics, our hospitals, are care. blood our full strategic the to of those clean organizations that physician sales relationships cover which to years points separate we labs strong. has commercial relationships, take structure advantage had partners each good priority. team over with a of while moving of one covers sales a other and of and works as
global structures we combined organizational place with product across are completing other go-to-market the and analyses regions, the Additionally, in portfolio.
close QuidelOrtho the and in be year-over-year, ready strong of in grew to the finalize our to In January primary industry-wide markets XX%. year, XXXX of U.S. automation as focus our base commercial organization, of with XXXX For the despite commercial the enter and supply vitro's analyzer major our integration is meantime, integrated grew as and the China installed scheduled. chains, challenges remainder XX%
As subside, lab the those analyzers. mid- with we headwinds segment throughput our expect integrated and high into further penetration
domestic rapid home COVID over federal The government point-of-care from purchase our multiple its to manufacturers. XXX to million Moving announced tests additional tests. intent
to stage. final We and continue the to have in the advanced participate process
our uncertain. level some believe we timing While success is likely, at the is
expand retail therefore, availability. work market are, the including on ways test, In to additional COVID government to not any revenue retail we continue distributors our We in all for major with our XXXX guidance.
a such distributors. respiratory During and the retail as we quarter, We in hand influenza major respiratory this we're current their And inventories moderate good all on are a supply manufacturer. at through returned season, became and up label strong surges demand if that one, scale chain, in for confronted with we can output, for current shape and including private shelves pathogens we quickly RSV. of to believe combination factory
to organization, a supply entrants agreements now particular throughout believe sole-source pivot our especially chains. driving away quickly operational could in excellence leveraging to be emphasis We're our at relative hard We advantage space. work on strengthen to sheet competitive ability our operational from the Turning to excellence. balance with that competitive supplier smaller a
As believe example, which chips record current become but companies will to quarter, and third able All that grew supply improved not are equally. the of customers. suppliers materials. must-have have all supply of generally, on and supply consistency an are our in of stocks brought facing safety semiconductor a we we chain address track reliable product prospective for a challenges, them of In the future, more our many raw the
manufactures million capacity tests and manufacture we million manufacture week. XX at approximately Sofia have XXX -- to capacity, online per Looking up We week that to X our get per we kits our up in capacity that labs to week. Rochester to at capacity instrument XXXX, our lines per have XX sequentially. to excuse McKellar At site flat at site, our us QuickVue tests Rutherford we will XX orders the million site, have slides open manufacturing And additional million me, have the up now coming two week. relatively slides with per
quarter, We to to plan the in of expect a the increase we end place clearing that have back modestly orders by fourth XXXX. begin in but
commercialization our current months, chain instrument begun This season. capacity low-volume validation us respiratory of two instrument of the the expand supply overcome challenges, our couple and Savanna Europe, Middle completed and ramping cartridge Africa allows past and the for manufacturing first of setup manufacturing over Lastly, lines. the to we've East
be fourth number second we lines Our meet the these is should during sufficient to We pull-through more ship. given believe expected of low-volume be line than to online quarter. expect brought to demand the instruments X
expected mid-XXXX, U.S. Our two up and our be automated by to running commercial are high-volume lines launch. of ahead
the priority deployment. capital last consistent Our strategic cash strategic to funds healthy and allocate flexibility us give is sheet balance A toward several priorities. generation
M&A. are priorities debt expansion, capacity and paydown, R&D lastly, Our investment, repurchase share manufacturing strategic
need margin consistently The the intend as each take During program two shares our back the authorization. quarter, buy flow our don't our We strategy, don't repurchase advantage announced of is we authorized. growth durability the of that $XXX dislocation complete of share a in entire quarter, reflects We in of of the view million we $XXX and the long-term million third the years we repurchase broad on program base the and recurring to a put confidence sustainability repurchase cash value a our our to in profile. revenues, what shares. to place
from debt our historically slowdowns. relative economic our repurchase pay of our intend in share accretion insulated and third debt in ahead, paydown. The looking down, relatively to program market the particularly quarter, prudently was we to balance While has attractive been diagnostic repurchase the vitro program share
concerns However, macro uncertain we environment. are an acutely and aware of leverage
each respiratory-related are our and guidance. to from million have flows preference required especially results I'd pay our XXXX are like turn greater of long-term benefit that further QX that, $XXX We plan. cash to year more, Joe? revenues, Joe financial even to With debt pay down and to a the down over than call and COVID as discuss other our to
